Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 23, Supplement—December 2017
SUPPLEMENT ISSUE
Global Health Security Supplement
Prevent

CDC Activities for Improving Implementation of Human Papillomavirus Vaccination, Cervical Cancer Screening, and Surveillance Worldwide

Virginia SenkomagoComments to Author , Denise Duran, Anagha Loharikar, Terri B. Hyde, Lauri E. Markowitz, Elizabeth R. Unger, and Mona Saraiya
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Figure

Worldwide cervical cancer incidence and human papillomavirus (HPV) vaccination status. A) Estimated cervical cancer incidence rates per 100,000 persons in 2012. Source: GLOBOCAN, 2012, WHO. B) Progress in HPV vaccine introduction in national immunization programs, 2016. Source: WHO, 2016. Many countries with high cervical cancer incidence rates (primarily countries in sub-Saharan Africa, Asia, and a few in Latin America) have not yet introduced HPV vaccination in their national immunization prog

Figure. Worldwide cervical cancer incidence and human papillomavirus (HPV) vaccination status. A) Estimated cervical cancer incidence rates per 100,000 persons in 2012. Source: GLOBOCAN, 2012, WHO. B) Progress in HPV vaccine introduction in national immunization programs, 2016. Source: WHO, 2016. Many countries with high cervical cancer incidence rates (primarily countries in sub-Saharan Africa, Asia, and a few in Latin America) have not yet introduced HPV vaccination in their national immunization programs. Cervical cancer can also be prevented by screening and treatment for precancerous lesions; incidence and mortality rates in high-income countries have decreased largely because of effective screening programs. Data for cervical cancer screening coverage worldwide are limited; 2002 World Health Survey data showed that the proportion of women who had a Papanicolaou test in the previous 3 years greatly varied among countries; 11%–83% in industrialized countries, and 1%–73% in developing countries (5). WHO, World Health Organization.

Main Article

References
  1. International Agency for Research on Cancer. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.0, cancer incidence and mortality worldwide: IARC Cancer Base No. 11, 2013. Lyon (France): International Agency for Research on Cancer 2014 [cited 2017 Sep 27]. http://publications.iarc.fr/Databases/Iarc-Cancerbases/Globocan-2012-Estimated-Cancer-Incidence-Mortality-And-Prevalence-Worldwide-In-2012-V1-0-2012
  2. Schlecht  NF, Kulaga  S, Robitaille  J, Ferreira  S, Santos  M, Miyamura  RA, et al. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA. 2001;286:3106–14. DOIPubMedGoogle Scholar
  3. Saraiya  M, Unger  ER, Thompson  TD, Lynch  CF, Hernandez  BY, Lyu  CW, et al.; HPV Typing of Cancers Workgroup. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107:djv086. DOIPubMedGoogle Scholar
  4. Schiffman  M, Kjaer  SK. Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia. J Natl Cancer Inst Monogr. 2003;31:14–9. DOIPubMedGoogle Scholar
  5. Gakidou  E, Nordhagen  S, Obermeyer  Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5:e132. DOIPubMedGoogle Scholar
  6. International Agency for Research on Cancer. IARC handbooks of cancer prevention. Vol. 10 [cited 2017 Sep 27]. http://www.iarc.fr/en/publications/pdfs-online/prev/handbook10/
  7. World Health Organization. Immunization vaccines and biologicals database, April 2017. Geneva: The Organization; 2017.
  8. World Health Organization. Guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, 2013 [cited 2017 Sep 27]. http://www.who.int/reproductivehealth/publications/cancers/screening_and_treatment_of_precancerous_lesions/en/
  9. Council on Foreign Relations. The emerging global health crisis: noncommunicable diseases in low-and middle-income countries, 2014. Independent Task Force Report No. 72 [cited 2017 Sep 27]. http://www.cfr.org/diseases-noncommunicable/emerging-global-health-crisis/p33883
  10. Centers for Disease Control and Prevention. CDC’s strategic framework for global immunization, 2016–2020, 2016 [cited 2017 Sep 27]. https://www.cdc.gov/globalhealth/immunization/docs/global-immunization-framework-508.pdf
  11. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec. 2009;84:118–31.PubMedGoogle Scholar
  12. World Health Organization. Report of the meeting on HPV vaccine coverage and impact monitoring, November 16–17, 2009. Geneva: The Organization; 2010 [cited 2017 Oct 19] http://apps.who.int/iris/bitstream/10665/70305/1/WHO_IVB_10.05_eng.pdf
  13. World Health Organization. Recommendations to assure the quality, safety and efficacy of recombinant human papillomavirus virus-like particle vaccines. Geneva: The Organization; 2015 [cited 2017 Oct 19]. http://www.who.int/biologicals/IPV_FINAL_for_BS2233_07072014(2).pdf
  14. Gavi, The Vaccine Alliance. Human papillomavirus vaccine support, 2017 [cited 2017 Feb 15]. http://www.gavi.org/support/nvs/human-papillomavirus/
  15. PATH Publications and London School of Hygiene and Tropical Medicine. HPV vaccine lessons learned. RHO Cervical Cancer, 2014–2016 [cited 2017 Feb 15]. http://www.rho.org/HPVlessons/
  16. Meeting of the Strategic Advisory Group of Experts on Immunization. October 2016: conclusions and recommendations. Wkly Epidemiol Rec. 2016;91:561–82.PubMedGoogle Scholar
  17. Friedman  AL, Oruko  KO, Habel  MA, Ford  J, Kinsey  J, Odhiambo  F, et al. Preparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Health. 2014;14:855. DOIPubMedGoogle Scholar
  18. Centers for Disease Control and Prevention (CDC). Progress toward implementation of human papillomavirus vaccination—the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep. 2011;60:1382–4.PubMedGoogle Scholar
  19. Markowitz  LE, Tsu  V, Deeks  SL, Cubie  H, Wang  SA, Vicari  AS, et al. Human papillomavirus vaccine introduction—the first five years. Vaccine. 2012;30(Suppl 5):F139–48. DOIPubMedGoogle Scholar
  20. Pan American Health Organization/World Health Organization/Centers for Disease Control and Prevention. Integrating HPV testing in cervical cancer screening programs: a manual for program managers, 2016 [cited 2017 Sep 27]. http://iris.paho.org/xmlui/handle/123456789/31393
  21. Joint United Nations Programme on HIV and AIDS. The George W. Bush Institute, the U.S. Department of State, Susan G. Komen for the Cure, and UNAIDS announce a new women’s health initiative (press release) [cited 2017 Sep 27]. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2011/september/20110913pinkribbonredribbon
  22. Sangrajrang  S, Laowahutanont  P, Wongsena  M, Muwonge  R, Karalak  A, Imsamran  W, et al. Comparative accuracy of Pap smear and HPV screening in Ubon Ratchathani in Thailand. Papillomavirus Res. 2017;3:30–5. DOIPubMedGoogle Scholar
  23. Drummond  JL, Were  MC, Arrossi  S, Wools-Kaloustian  K. Cervical cancer data and data systems in limited-resource settings: Challenges and opportunities. Int J Gynaecol Obstet. 2017;138(Suppl 1):33–40. DOIPubMedGoogle Scholar
  24. Centers for Disease Control and Prevention. CDC Foundation and George W. Bush Institute partner in $3.6 million grant to address global cervical cancer. April 16, 2014 [cited 2017 Sep 27]. https://www.cdcfoundation.org/pr/2014/cdc-foundation-bush-institute-partnership-to-address-global-cervical-cancer
  25. Centers for Disease Control and Prevention Foundation. Improving data for decision-making in global cervical cancer programs (IDCCP). Accelerating action on human papillomavirus and cervical cancer prevention and control (APEC) Conference: Implementing Policy Recommendations Workshop; August 23, 2016; Lima, Peru [cited 2017 Sep 27]. http://mddb.apec.org/Documents/2016/HWG/HWG-LSIF-WKSP/16_hwg-lsif_wksp_006.pdf
  26. Joseph  R, Manosoontorn  S, Petcharoen  N, Sangrajrang  S, Senkomago  V, Saraiya  M. Assessing cervical cancer screening coverage using a population-based behavioral risk factor survey—Thailand, 2010. J Womens Health (Larchmt). 2015;24:966–8. DOIPubMedGoogle Scholar
  27. Wang  B, He  M, Chao  A, Engelgau  MM, Saraiya  M, Wang  L, et al. Cervical cancer screening among adult women in China, 2010. Oncologist. 2015;20:627–34. DOIPubMedGoogle Scholar
  28. Buchanan Lunsford  N, Ragan  K, Lee Smith  J, Saraiya  M, Aketch  M. Environmental and psychosocial barriers to and benefits of cervical cancer screening in Kenya. Oncologist. 2017;22:173–81. DOIPubMedGoogle Scholar
  29. Centers for Disease Control and Prevention. Field Epidemiology Training Program: where we work [cited 2017 Feb 17]. https://www.cdc.gov/globalhealth/healthprotection/fetp/where/index.html
  30. The Cancer Atlas. Reliable monitoring of cancer cases and deaths is essential for successful cancer management plans, 2017 [cited 2017 Sep 27]. http://canceratlas.cancer.org/taking-action/cancer-registries/
  31. International Agency for Research on Cancer (IARC). WHO global initiative for cancer registry development (GICR), 2017 [cited 2017 Sep 27]. http://gicr.iarc.fr/
  32. Saraiya  M, Tangka  FK, Asma  S, Richardson  LC. Importance of economic evaluation of cancer registration in the resource limited setting: Laying the groundwork for surveillance systems. Cancer Epidemiol. 2016;45(Suppl 1):S1–3. DOIPubMedGoogle Scholar

Main Article

Page created: November 20, 2017
Page updated: November 20, 2017
Page reviewed: November 20, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external